Robotic Pelvic Oncology, Department of Urology, University College London Hospital, London.
Department of Urology, AIIMS, Rishikesh.
Urology. 2021 Aug;154:8-15. doi: 10.1016/j.urology.2021.03.010. Epub 2021 Mar 26.
Neoadjuvant chemotherapy followed by radical cystectomy is the standard of care for muscle invasive non-metastatic bladder cancer patients. While cisplatin based neoadjuvant chemotherapy has been recommended, systemic therapy in a neoadjuvant setting for cisplatin ineligible patients still needs to be addressed. Various strategies like split dosing cisplatin chemotherapy, carboplatin based chemotherapy and taxanes based chemotherapy have been tried as neoadjuvant therapy for cisplatin ineligible patients. Immunotherapy is a promising tool in this regard with a need for the development of predictive and prognostic biomarkers which can bring out the true potential of these immunotherapeutic agents.
新辅助化疗后行根治性膀胱切除术是非转移性肌层浸润性膀胱癌患者的标准治疗方法。虽然推荐使用顺铂为基础的新辅助化疗，但对于不适合使用顺铂的患者，仍需在新辅助治疗中使用系统治疗。已经尝试了各种策略，如顺铂化疗的分割剂量、卡铂为基础的化疗和紫杉烷类为基础的化疗，作为不适合使用顺铂患者的新辅助治疗。免疫疗法在这方面是一种很有前途的工具，需要开发预测和预后的生物标志物，以充分发挥这些免疫治疗药物的潜力。
